Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Follow-Up Questions
What is the price performance of GLMD stock?
The current price of GLMD is $1.27, it has increased 6.95% in the last trading day.
What are the primary business themes or industries for Galmed Pharmaceuticals Ltd?
Galmed Pharmaceuticals Ltd belongs to Biotechnology industry and the sector is Health Care
What is Galmed Pharmaceuticals Ltd market cap?
Galmed Pharmaceuticals Ltd's current market cap is $6.9M
Is Galmed Pharmaceuticals Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Galmed Pharmaceuticals Ltd, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
